✦ LIBER ✦

Depression, Anxiety, and Relevant Cognitions in Persons with Mental Retardation

✍ Scribed by Elizabeth Glenn; Elson M. Bihm; William J. Lammers

Book ID: 110418006
Publisher: Springer US
Year: 2003
Tongue: English
Weight: 36 KB
Volume: 33
Category: Article
ISSN: 1573-3432
DOI: 10.1023/a:1022282521625

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of Anxiety and Depression in

Assessment of Anxiety and Depression in Adolescents with Mental Retardation

✍ Gabriele Masi; Paola Brovedani; Maria Mucci; Letizia Favilla 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 58 KB

Diagnosis and management of depression a

Diagnosis and management of depression and suicidal behavior in persons with severe mental retardation

✍ Frank J. Menolascino; Jessica Lazer; Jack A. Stark 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 920 KB

Depression in adults with mild mental re

Depression in adults with mild mental retardation: Are cognitive variables involved?

✍ Christine Maguth Nezu; Arthur M. Nezu; Jami L. Rothenberg; Lisa DelliCarpini; Ir 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 715 KB

The Relationship Between Depression and

The Relationship Between Depression and Feeding Disorder Symptoms Among Persons with Severe and Profound Mental Retardation

✍ Stephen B. Mayville; Johnny L. Matson; Rinita B. Laud; Chris Cooper; David E. Ku 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 72 KB

Diagnosis and treatment of depression in

Diagnosis and treatment of depression in patients with mental retardation

✍ David S. Janowsky; John M. Davis 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 371 KB

Psychopharmacology of mood disorders in

Psychopharmacology of mood disorders in persons with mental retardation and autism

✍ Hellings, Jessica A. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

The ever-growing range of designer drugs such as selective serotonin reuptake inhibitors (SSRIs) and other new antidepressants, atypical antipsychotic agents, and antiseizure medications may improve treatment efficacy and safety for persons with mood disorders and mental retardation (MR) and autism.